The substantial therapeutic promise of GLP-1 receptor agonists in reproductive medicine, especially for obese women with PCOS, is highlighted by the amalgamation of clinical, molecular, and animal data. This evidence concerns the gene GLP1R and polycystic ovary syndrome.